BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines upfront License & Development Milestone Fees ($M) ($M)
Form 10-Q / 10-K Collaborative Arrangements Note (XBRL) & MD&A
Latest, Q2 2026
23.3
Period ended Jun 30, 2026
Change on a year earlier
+13.7%
20.5 in Q2 2025
History
24 quarters
Since Q1 2019
Sources
16
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up upfront license & development milestone fees ($m)
Cite this data
StockData. (2026). BeOne Medicines Upfront License & Development Milestone Fees ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_upfront_milestone_tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.